Ivabradine for the treatment of stable angina pectoris in octogenarians.
OBJECTIVE
In patients >80 years (octogenarians), there is an increased incidence of bradycardia due to age-related alteration of the sinus node, AV node, and the conduction system. Therefore, the treatment of angina pectoris with beta-blockers may be limited by bradycardia. The REDUCTION multicenter study evaluated the efficacy of ivabradine in stable angina pectoris in everyday practice. This subgroup analysis evaluated the efficacy and safety of ivabradine in octogenarians.


METHODS
A total of 4,954 patients were included in the REDUCTION study for treatment of stable angina pectoris. This group included 382 octogenarians (mean age 83 ± 2.9 years) who were followed up over 4 months. Patients were treated with ivabradine in flexible doses (2.5, 5, or 7.5 mg bid). Heart rate (HR), angina pectoris attacks, nitrate consumption, overall efficacy, and tolerance were evaluated.


RESULTS
After 4 months of treatment with ivabradine, HR was reduced by 12.0 ± 12.0 bpm from 83.0 ± 15.4 to 71.0 ± 10.1 bpm (p < 0.0001). Angina pectoris attacks were reduced from 3.0 ± 4.6 to 0.8 ± 1.8 per week (p < 0.0001). Consumption of nitrates decreased from 4.2 ± 5.1 to 1.2 ± 2.7 (p < 0.0001). Four patients reported suspected adverse drug reactions. In one patient a syncope occurred. There was no symptomatic bradycardia reported. Efficacy and tolerance were assessed as 'very good/good' for 95 and 99%.


CONCLUSIONS
The results demonstrate that ivabradine efficiently reduces HR, number of angina attacks, and nitrate consumption in octogenarian patients. The treatment was safe and well tolerated without relevant bradycardia.
Koester
Ralf
R
Clinic for General and Interventional Cardiology, University Heart Center Hamburg, Martinistrasse 52, 20246, Hamburg, Germany. rkoester@uke.uni-hamburg.de
Kaehler
Jan
J
Meinertz
Thomas
T
D000369:Aged, 80 and over; D000787:Angina Pectoris / Q000188:drug therapy* / Q000453:epidemiology*; D001552:Benzazepines / Q000627:therapeutic use*; D001919:Bradycardia / Q000453:epidemiology*; D015897:Comorbidity; D064420:Drug-Related Side Effects and Adverse Reactions / Q000453:epidemiology*; D005260:Female; D006801:Humans; D015994:Incidence; D000077550:Ivabradine; D008297:Male
D001552:Benzazepines; D000077550:Ivabradine
Am Heart J. 2010 Apr;159(4):508-517.e1
20362707
JAMA. 1992 Sep 16;268(11):1417-22
1512909
Clin Res Cardiol. 2007 Sep;96(9):585-92
17593316
N Engl J Med. 2000 Jun 22;342(25):1907-9
10861329
Eur Heart J. 2006 Jun;27(11):1341-81
16735367
Circulation. 1976 Sep;54(3):522-3
947585
Z Kardiol. 2003 Jun;92(6):501-21
12905980
Clin Res Cardiol. 2010 Oct;99(10):665-72
20454968
Eur Heart J. 2005 Dec;26(23):2529-36
16214830
N Engl J Med. 2000 Jun 22;342(25):1887-92
10861325
Circulation. 1967 Jun;35(6):1073-83
6026199
Clin Res Cardiol. 2006 Jul;95(7):360-7
16741630
Clin Res Cardiol. 2009 Aug;98(8):477-86
19479183
J Am Coll Cardiol. 2007 Aug 28;50(9):823-30
17719466
Sci Am. 1977 Oct;237(4):132-40
905817
Circulation. 2007 Dec 4;116(23):2762-72
17998462
Eur Heart J. 2009 Oct;30(19):2337-45
19720635
Clin Res Cardiol. 2011 Jan;100(1):29-36
20644943
Eur Heart J. 1999 Dec;20(24):1791-8
10581137
Circulation. 1991 Apr;83(4):1263-70
1901527
Clin Res Cardiol. 2008 Nov;97(11):811-9
18648727
Clin Res Cardiol. 2008 Sep;97(9):575-7
18536866
Lancet. 2008 Sep 6;372(9641):807-16
18757088
Eur Heart J. 2009 Mar;30(5):540-8
19136486
Circulation. 2003 Feb 18;107(6):817-23
12591750
Drugs. 2004;64(16):1757-65
15301560
Cardiol Clin. 1999 Feb;17(1):17-34
10093763
Am Heart J. 2009 Oct;158(4):e51-7
19781403
Lancet. 2008 Sep 6;372(9641):817-21
18757091
JAMA. 2001 Aug 8;286(6):708-13
11495621
Cardiology. 2009;114(2):116-25
19468225